

Enhanced Annual Drug List Updates

October 2020

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
ASMANEX HFA (mometasone furoate inhal aerosol suspension 50 mcg/act)	Brand	Addition, Preferred Status
BAQSIMI ONE PACK (glucagon nasal powder 3 mg/dose)	Brand	Addition, Preferred Status
BAQSIMI TWO PACK (glucagon nasal powder 3 mg/dose)	Brand	Addition, Preferred Status
DOVATO (dolutegravir sodium-lamivudine tab 50-300 mg (base eq))	Brand	Addition, Preferred Status
DULERA (mometasone furoate-formoterol fumarate aerosol 50-5 mcg/act)	Brand	Addition, Preferred Status
ESTRING (estradiol vaginal ring 2 mg (7.5 mcg/24hrs))	Brand	Addition, Preferred Status
GVOKE HYPOPEN (glucagon subcutaneous solution auto-injector 0.5 mg/0.1ml)	Brand	Addition, Preferred Status
GVOKE HYPOPEN (glucagon subcutaneous solution auto-injector 1 mg/0.2ml)	Brand	Addition, Preferred Status
HARVONI (ledipasvir-sofosbuvir pellet pack 33.75-150 mg)	Brand	Addition, Preferred Status
HARVONI (ledipasvir-sofosbuvir pellet pack 45-200 mg)	Brand	Addition, Preferred Status
JULUCA (dolutegravir sodium-ripirovirine hcl tab 50-25 mg (base eq))	Brand	Addition, Preferred Status
NEXLETOL (bempedoic acid tab 180 mg)	Brand	Addition, Preferred Status
PAROMOMYCIN SULFATE (paromomycin sulfate cap 250 mg)	Brand	Addition, Preferred Status
SOLIQUA 100/33 (insulin glargine-lixisenatide sol pen-inj 100-33 unit-mcg/ml)	Brand	Addition, Preferred Status
SOVALDI (sofosbuvir pellet pack 150 mg)	Brand	Addition, Preferred Status
SOVALDI (sofosbuvir pellet pack 200 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 100 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 140 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 20 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 50 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 70 mg)	Brand	Addition, Preferred Status
SPRYCEL (dasatinib tab 80 mg)	Brand	Addition, Preferred Status
TALZENNA (talazoparib tosylate cap 0.25 mg (base equivalent))	Brand	Addition, Preferred Status
TALZENNA (talazoparib tosylate cap 1 mg (base equivalent))	Brand	Addition, Preferred Status
XULTOPHY 100/3.6 (insulin degludec-liraglutide sol pen-inj 100-3.6 unit-mg/ml)	Brand	Addition, Preferred Status
ZEPOSIA (ozanimod hcl cap 0.92 mg)	Brand	Addition, Preferred Status
ZEPOSIA 7-DAY STARTER PACK (ozanimod cap pack 4 x 0.23 mg & 3 x 0.46 mg)	Brand	Addition, Preferred Status
ZEPOSIA STARTER KIT (ozanimod cap pack 4 x 0.23 mg & 3 x 0.46 mg & 30 x 0.92 mg)	Brand	Addition, Preferred Status
ZIEXTENZO (pegfilgrastim-bmez soln prefilled syringe 6 mg/0.6ml)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.